Stoke Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Good morning, everyone. Thank you for joining the 21st Annual Needham Healthcare Conference. My name is Joey Stringer, and I'm one of the biotech analysts at Needham and Company. It's my pleasure to introduce our next presenting company, Stoke Therapeutics.
Joining us today from Stoke is CEO Ed Kaye. For those of you joining us on the webcast, if you wish to ask a question, please do so at any time. You can use the chat box at the bottom of your screen to submit a question.
With that, we'll get started. I'll turn it over to Ed for opening remarks and then we'll go ahead and start with the chat.
Great, thanks. Thank you, Joey, and thanks for the invitation here. So to explain Stoke, it's an RNA-splicing company that was started in 2014. And it really came out of a concept that Adrian Krainer -- who was the inventor of SPINRAZA -- had, and that was that if you change splicing, you could actually increase the amount of protein that was
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |